Kaitlin Schaefer
University of California, San Francisco
9 Papers
33 Citations
Kaitlin Schaefer is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Chemistry & Affinity maturation. The author has an hindex of 6, co-authored 9 publications. Previous affiliations of Kaitlin Schaefer include University of California, Berkeley & Icahn School of Medicine at Mount Sinai.
Chat about Author
Papers
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.
David E. Gordon,Joseph Hiatt,Mehdi Bouhaddou,Veronica V. Rezelj,Svenja Ulferts,Hannes Braberg,Alexander S. Jureka,Kirsten Obernier,Jeffrey Z. Guo,Jyoti Batra,Robyn M. Kaake,Andrew R. Weckstein,Tristan W. Owens,Meghna Gupta,Sergei Pourmal,Erron W. Titus,Merve Cakir,Margaret Soucheray,Michael J. McGregor,Zeynep Cakir,Gwendolyn M. Jang,Matthew J. O’Meara,Tia A. Tummino,Ziyang Zhang,Helene Foussard,Ajda Rojc,Yuan Zhou,Dmitry Kuchenov,Ruth Hüttenhain,Jiewei Xu,Manon Eckhardt,Danielle L. Swaney,Jacqueline M. Fabius,Manisha Ummadi,Beril Tutuncuoglu,Ujjwal Rathore,Maya Modak,Paige Haas,Kelsey M. Haas,Zun Zar Chi Naing,Ernst H. Pulido,Ying Shi,Inigo Barrio-Hernandez,Danish Memon,Eirini Petsalaki,Alistair Dunham,Miguel Correa Marrero,David F. Burke,Cassandra Koh,Thomas Vallet,Jesus A. Silvas,Caleigh M. Azumaya,Christian B. Billesbølle,Axel F. Brilot,Melody G. Campbell,Melody G. Campbell,Amy Diallo,Miles Sasha Dickinson,Devan Diwanji,Nadia Herrera,Nick Hoppe,Huong T. Kratochvil,Yanxin Liu,Gregory E. Merz,Michelle Moritz,Henry C. Nguyen,Carlos Nowotny,Cristina Puchades,Alexandrea N. Rizo,Ursula Schulze-Gahmen,Amber M. Smith,Ming Sun,Iris D. Young,Jianhua Zhao,Daniel Asarnow,Justin T Biel,Alisa Bowen,Julian R. Braxton,Jen Chen,Cynthia M. Chio,Un Seng Chio,Ishan Deshpande,Loan Doan,Bryan Faust,Sebastian Flores,Mingliang Jin,Kate Kim,Victor L Lam,Fei Li,Junrui Li,Y. Li,Yang Li,Xi Liu,Megan Lo,Kyle E. Lopez,Arthur Alves de Melo,Frank R. Moss,Phuong Nguyen,Joana Paulino,Komal Ishwar Pawar,Jessica K. Peters,Thomas H. Pospiech,Maliheh Safari,Smriti Sangwan,Kaitlin Schaefer,Paul V. Thomas,Aye C. Thwin,Raphael Trenker,Eric Tse,Tsz Kin Martin Tsui,Feng Wang,Natalie Whitis,Zanlin Yu,Kaihua Zhang,Yang Zhang,Fengbo Zhou,Daniel J. Saltzberg,Anthony J. Hodder,Amber S. M. Shun-Shion,Daniel M. Williams,Kris M. White,Romel Rosales,Thomas Kehrer,Lisa Miorin,Elena Moreno,Arvind H. Patel,Suzannah J. Rihn,Mir M. Khalid,Albert Vallejo-Gracia,Parinaz Fozouni,Parinaz Fozouni,Camille R. Simoneau,Camille R. Simoneau,Theodore L. Roth,David Wu,Mohd Anisul Karim,Maya Ghoussaini,Ian Dunham,Francesco Berardi,Sebastian Weigang,Maxime Chazal,Jisoo Park,James Logue,Marisa McGrath,Stuart Weston,Robert Haupt,C. James Hastie,Matthew Elliott,Fiona Brown,Kerry A. Burness,Elaine Reid,Mark Dorward,Clare Johnson,Stuart G. Wilkinson,Anna Geyer,Daniel M. Giesel,Carla Baillie,Samantha Raggett,Hannah Leech,Rachel Toth,Nicola Goodman,Kathleen C. Keough,Abigail L. Lind,Reyna J. Klesh,Kafi R. Hemphill,Jared Carlson-Stevermer,Jennifer Oki,Kevin Holden,Travis J. Maures,Katherine S. Pollard,Katherine S. Pollard,Andrej Sali,David A. Agard,Yifan Cheng,James S. Fraser,Adam Frost,Natalia Jura,Tanja Kortemme,Aashish Manglik,Daniel R. Southworth,Robert M. Stroud,Dario R. Alessi,Paul Davies,Matthew B. Frieman,Trey Ideker,Carmen Abate,Nolwenn Jouvenet,Nolwenn Jouvenet,Georg Kochs,Brian K. Shoichet,Melanie Ott,Melanie Ott,Massimo Palmarini,Kevan M. Shokat,Adolfo García-Sastre,Jeremy A. Rassen,Robert Grosse,Oren S. Rosenberg,Kliment A. Verba,Christopher F. Basler,Marco Vignuzzi,Andrew A. Peden,Pedro Beltrao,Nevan J. Krogan +203 more
TL;DR: The authors identified shared biology and host-directed drug targets to prioritize therapeutics with potential for rapid deployment against current and future coronavirus outbreaks, and found that individuals with genotypes corresponding to higher soluble IL17RA levels in plasma are at decreased risk of COVID-19 hospitalization.
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Michael Schoof,Bryan Faust,R.A. Saunders,Smriti Sangwan,Veronica V. Rezelj,Nick Hoppe,Morgane Boone,Christian B. Billesbølle,Cristina Puchades,Caleigh M. Azumaya,Huong T. Kratochvil,M. Zimanyi,Ishan Deshpande,Jiahao Liang,S. Dickinson,Henry C. Nguyen,Cynthia M. Chio,Gregory E. Merz,Michael C. Thompson,Devan Diwanji,Kaitlin Schaefer,Aditya A. Anand,Niv Dobzinski,Beth S. Zha,Camille R. Simoneau,Camille R. Simoneau,Kristoffer E. Leon,Kristoffer E. Leon,Kris M. White,Un Seng Chio,Meghna Gupta,Mingliang Jin,Fei Li,Yanxin Liu,Kaihua Zhang,David Bulkley,Ming Sun,Amber M. Smith,Alexandrea N. Rizo,Frank R. Moss,Axel F. Brilot,Sergei Pourmal,Raphael Trenker,Thomas H. Pospiech,Sayan Gupta,Benjamin Barsi-Rhyne,Vladislav Belyy,A.W. Barile-Hill,Silke Nock,Yuwei Liu,Nevan J. Krogan,Corie Y. Ralston,Danielle L. Swaney,Adolfo García-Sastre,Melanie Ott,Melanie Ott,Marco Vignuzzi,Peter Walter,Aashish Manglik +58 more
TL;DR: Nanobodies that bind tightly to spike and efficiently neutralize SARS-CoV-2 in cells are reported, which enables aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia.
401
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
Colton J Bracken,Shion A. Lim,Paige Solomon,Nicholas J. Rettko,Duy P. Nguyen,Beth S. Zha,Kaitlin Schaefer,James Byrnes,Jie Zhou,Irene Lui,Jia Liu,Jia Liu,Katarina Pance,Xin X. Zhou,Kevin Leung,James A. Wells +15 more
TL;DR: This work constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD), identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats.
An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation
Michael Schoof,Bryan Faust,R.A. Saunders,Smriti Sangwan,Veronica V. Rezelj,Nick Hoppe,Nick Hoppe,Morgane Boone,Christian Billesboelle,Christian Billesboelle,Cristina Puchades,Caleigh M. Azumaya,Caleigh M. Azumaya,Huong T. Kratochvil,M. Zimanyi,Ishan Deshpande,Ishan Deshpande,Jiahao Liang,S. Dickinson,Henry C. Nguyen,Cynthia M. Chio,Gregory E Merz,Michael C. Thompson,Michael C. Thompson,Devan Diwanji,Devan Diwanji,Kaitlin Schaefer,Aditya A. Anand,Niv Dobzinski,Beth S. Zha,Camille R. Simoneau,Camille R. Simoneau,Kristoffer E. Leon,Kristoffer E. Leon,Kris M. White,Un Seng Chio,Un Seng Chio,Meghna Gupta,Mingliang Jin,Fei Li,Yanxin Liu,Kaihua Zhang,David Bulkley,Ming Sun,Amber M. Smith,Alexandrea N. Rizo,Frank R. Moss,Axel F. Brilot,Sergei Pourmal,Raphael Trenker,Thomas H. Pospiech,Sayan Gupta,Benjamin Barsi-Rhyne,Vladislav Belyy,A.W. Barile-Hill,Silke Nock,Yuwei Liu,Nevan J. Krogan,Corie Y. Ralston,Danielle L. Swaney,Adolfo García-Sastre,Melanie Ott,Melanie Ott,Marco Vignuzzi,Peter Walter,Aashish Manglik +65 more
TL;DR: Single-domain antibodies (nanobodies) are developed that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2, promising to yield a widely deployable, patient-friendly prophylactic and/or early infection therapeutic agent to stem the worst pandemic in a century.
An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation
Michael Schoof,Bryan Faust,R.A. Saunders,Smriti Sangwan,Rezelj,Nick Hoppe,Nick Hoppe,Morgane Boone,Christian B. Billesbølle,Christian B. Billesbølle,Cristina Puchades,Caleigh M. Azumaya,Huong T. Kratochvil,M. Zimanyi,Ishan Deshpande,Ishan Deshpande,Jiahao Liang,S. Dickinson,Henry C. Nguyen,Cynthia M. Chio,Gregory E. Merz,Michael C. Thompson,Devan Diwanji,Kaitlin Schaefer,Aditya A. Anand,Niv Dobzinski,Beth S. Zha,Camille R. Simoneau,Camille R. Simoneau,Kristoffer E. Leon,Kristoffer E. Leon,Kris M. White,Un Seng Chio,Meghna Gupta,Mingliang Jin,Fei Li,Yanxin Liu,Kaihua Zhang,David Bulkley,Ming Sun,Amber M. Smith,Alexandrea N. Rizo,Frank R. Moss,Axel F. Brilot,Sergei Pourmal,Raphael Trenker,Thomas H. Pospiech,Sayan Gupta,Benjamin Barsi-Rhyne,Belyy,A.W. Barile-Hill,Silke Nock,Nevan J. Krogan,Corie Y. Ralston,Danielle L. Swaney,Adolfo García-Sastre,Melanie Ott,Melanie Ott,Marco Vignuzzi,Peter Walter,Aashish Manglik +60 more
TL;DR: In this article, single-domain antibodies (nanobodies) are developed that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2, which may enable aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia, promising to yield a widely deployable, patient-friendly and/or early infection therapeutic agent to stem the worst pandemic in a century.